Company profile: BerGenBio
1.1 - Company Overview
Company description
- Provider of clinical-stage oncology therapeutics focused on first-in-class selective AXL kinase inhibitors for aggressive cancers, including bemcentinib (BGB324), a selective AXL inhibitor in clinical development for STK11 mutated NSCLC and severe respiratory infections.
Products and services
- Bemcentinib (BGB324): A first-in-class, selective AXL kinase inhibitor in clinical development targeting STK11-mutated NSCLC and severe respiratory infections, engineered to counter drivers of aggressive cancers
- AXL Kinase Inhibitor Development: Clinical-stage programs that develop AXL inhibitor products to treat multiple aggressive cancers, architected around the AXL kinase target
- Therapeutics Against Novel Drug Targets R&D: Oncology biotech research that engineers treatments against novel drug targets driving aggressive cancers, producing candidates like bemcentinib for a variety of cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BerGenBio
Imvaq Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imvaq Therapeutics company profile →
Tilt Biotherapeutics
HQ: Finland
Website
- Description: Provider of oncolytic viral cancer immunotherapies that enable tumor T-cell therapy by modifying the tumor microenvironment. Pipeline includes TILT-123 (cytokine-armed oncolytic adenovirus, in Phase 1), TILT-234 (Ad3 armed with human CD40L, ready for CMC/regulatory), TILT-321/322 (bispecific antibody-coding adenoviruses, discovery), and TILT-452 (preclinical), with clinical trial collaborations on TILT-123 with Merck KGaA and MSD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilt Biotherapeutics company profile →
Cellestia
HQ: Switzerland
Website
- Description: Provider of clinical-stage R&D therapies to control and modulate pathogenic gene expression via selective inhibition of transcription factors in the cell nucleus. Lead candidate CB-103 targets the CSL-NOTCH complex and is in Phase 2 for various cancers and GvHD, showing efficacy in multi-drug resistant cancers and autoimmune diseases. Pipeline includes preclinical assets for psoriasis, Sjogren’s, SLE, IBD and giant cell arteritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellestia company profile →
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
Lindis Blood Care
HQ: Germany
Website
- Description: Provider of a medical device for removing cancer cells from intraoperative blood during cancer surgeries to enable autologous blood transfusion (CATUVAB), and a multicenter clinical certification study (REMOVE) assessing the device’s efficacy and safety in tumor cell removal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lindis Blood Care company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BerGenBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BerGenBio
2.2 - Growth funds investing in similar companies to BerGenBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BerGenBio
4.2 - Public trading comparable groups for BerGenBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →